You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
輝瑞和Roivant成立專注於自身免疫性疾病治療的聯合生物技術公司Priovant Treeutics
格隆匯6月28日丨輝瑞(PFE.US)和Roivant(ROIV.US)週二表示,他們正在合作推出一家聯合生物技術公司Priovant Treeutics,旨在開發治療自身免疫性疾病的新療法。輝瑞擁有Priovant 25%的股權,這一合作伙伴關係是在9月份輝瑞與Roivant之間的一項交易中建立的,在交易中,輝瑞向Priovant授予了口服和外用布洛西替尼的全球開發權以及美國和日本的商業權。此外,輝瑞還將選擇性TYK2抑制劑羅薩替尼授權給Priovant。Priovant最近開始了一項單一的註冊第三階段研究,以評估口服佈雷波替尼治療皮肌炎的效果,並預計在2023年下半年進行一項針對系統性紅斑狼瘡的2b階段研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account